文献速递其他结缔组织病类风湿关节炎脊柱关节炎

自身免疫病患者COVID-19患病率与临床结局:系统综述与Meta分析

Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.
PubMed 文献 · Ann Rheum Dis · 2020-10-13

7项病例对照研究显示自身免疫病患者COVID-19风险显著高于对照(OR 2.19,95%CI 1.05-4.58,p=0.038)。65项研究共2766例合并COVID-19的自身免疫病患者中,住院率和死亡率分别为0.35(95%CI 0.23-0.50)和0.066(95%CI 0.036-0.12);糖皮质激素、csDMARDs及b/tsDMARDs-csDMARDs联合治疗增加不良结局风险,而b/tsDMARDs单药(尤其抗TNF制剂)与较低住院和死亡风险相关。

要点

  • 自身免疫病患者COVID-19风险显著高于对照(OR 2.19),主要与糖皮质激素使用相关。
  • 合并COVID-19者住院率0.35、死亡率0.066,糖皮质激素及联合治疗增加不良结局风险。
  • b/tsDMARDs单药尤其抗TNF制剂与较低住院和死亡风险相关,提示疫情期间安全性。

核心结论

  • 自身免疫病患者COVID-19风险增加,主要归因于糖皮质激素使用。
  • b/tsDMARDs单药与较低重症COVID-19风险相关,提示疫情期间安全性。

研究设计与样本

  • 系统综述与Meta分析,检索电子数据库纳入观察性和病例对照研究。
  • 7项病例对照研究比较自身免疫病与对照的COVID-19风险。
  • 65项研究共2766例合并COVID-19的自身免疫病患者评估临床结局。

主要发现

  • 自身免疫病患者COVID-19患病率为0.011(95%CI 0.005-0.025)。
  • 自身免疫病COVID-19风险显著高于对照(OR 2.19,95%CI 1.05-4.58,p=0.038)。
  • Meta回归显示糖皮质激素与COVID-19风险显著相关。
  • 合并COVID-19者住院率0.35(95%CI 0.23-0.50),死亡率0.066(95%CI 0.036-0.12)。
  • 糖皮质激素、csDMARDs及b/tsDMARDs-csDMARDs联合治疗增加不良结局风险,b/tsDMARDs单药尤其抗TNF制剂与较低住院和死亡风险相关。

临床怎么用

  • 评估自身免疫病患者COVID-19风险时应关注糖皮质激素使用。
  • b/tsDMARDs单药尤其抗TNF制剂在疫情期间可能具有较好安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases who are frequently treated with disease modifying therapies remains poorly understood. This meta-analysis aims to assess the prevalence and clinical outcomes of COVID-19 in autoimmune diseases. METHODS: Electronic databases were searched for observational and case-controlled studies. We sorted medications into glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologic or targeted synthetic DMARDs (b/tsDMARDs), which was also divided into monotherapy and b/tsDMARDs-csDMARDs combination therapy. RESULTS: We analysed 62 observational studies with a total of 319 025 patients with autoimmune diseases. The prevalence of COVID-19 was 0.011 (95% CI: 0.005 to 0.025). Meta-analysis of seven case-controlled studies demonstrated that the risk of COVID-19 in autoimmune diseases was significantly higher than in control patients (OR: 2.19, 95% CI: 1.05 to 4.58, p=0.038). Meta-regression analysis showed glucocorticoids were significantly associated with the risk of COVID-19. For clinical outcomes, we assessed 65 studies with 2766 patients with autoimmune diseases diagnosed with COVID-19. The rates of hospitalisation and mortality were 0.35 (95% CI: 0.23 to 0.50) and 0.066 (95% CI: 0.036 to 0.12), respectively. Glucocorticoids, csDMARDs and b/tsDMARDs-csDMARDs combination therapy increased the risk of these outcomes, whereas b/tsDMARDs monotherapy, particularly antitumour necrosis factor agents, were associated with a lower risk of hospitalisation and death. CONCLUSIONS: Our meta-analysis demonstrated that patients with autoimmune diseases had an increased risk of COVID-19, primarily attributed to glucocorticoid use. b/tsDMARDs monotherapy was associated with a lower risk of severe COVID-19 suggesting its safety in the COVID-19 pandemic.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Akiyama S, Hamdeh S, Micic D, et al. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis. 2020. PMID: 33051220. doi:10.1136/annrheumdis-2020-218946

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。